Ovarian carcinoma (high-grade serous predominant) · line 2 · Carboplatin + Gemcitabine + Bevacizumab (platinum-sensitive recurrent ovarian, OCEANS regimen)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-CARBO-GEM-BEV-OVARIAN |
| ID | IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-OCEANS-AGHAJANIAN-2012 |
Notes
ESCAT IB. OCEANS regimen — primary platinum-sensitive 2L recommendation in UA setting (full NSZU coverage of all components).
Used By
Algorithms
ALGO-OVARIAN-2L- ALGO-OVARIAN-2L